[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.216.242. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Capitol Health Call
March 9, 2011

Delay for Generics

JAMA. 2011;305(10):987. doi:10.1001/jama.2011.263

Legislation intended to limit pharmaceutical manufacturers from reimbursing generic brand drug makers to keep generic versions of patented products off the market was reintroduced in the Senate on January 25.

The Preserve Access to Affordable Generics Act (S 27 [ http://thomas.loc.gov]) would amend the Federal Trade Commission Act and ban “pay-to-delay” agreements between brand name and generic pharmaceutical manufacturers in which a generic drug maker receives anything of value or agrees to limit or forgo research, development, manufacturing, or sales of a generic drug for any period of time.

First Page Preview View Large
First page PDF preview
First page PDF preview
×